Share Price and Basic Stock Data
Last Updated: December 8, 2025, 4:34 pm
| PEG Ratio | -0.47 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
EP Biocomposites Ltd operates in the waste management sector, a field that is increasingly gaining traction in India as sustainability becomes a priority. As of the latest report, the company’s share price is ₹100, and its market capitalization stands at ₹16.8 Cr. Revenue has shown a fluctuating trend, with sales reaching ₹5.30 Cr in March 2022, before declining to ₹3.68 Cr in March 2023. However, the recently reported figures indicate a rebound, with sales at ₹4.40 Cr in September 2023 and projected to rise to ₹7.04 Cr by March 2024. This pattern may reflect the company’s efforts to adapt to market demands and operational efficiencies. Moreover, the company has shown a consistent focus on expanding its revenue base, which is crucial for long-term sustainability in a competitive landscape.
Profitability and Efficiency Metrics
Profitability metrics reveal a mixed performance for EP Biocomposites. The operating profit margin (OPM) recorded a significant decline, dropping to 5.91% in September 2023 from a high of 19.43% in March 2022. This fluctuation raises concerns about cost management, especially as operating expenses have also risen, reaching ₹4.14 Cr in September 2023. More positively, the net profit for the same quarter was ₹0.22 Cr, indicating the company still managed to turn a profit despite rising costs. The interest coverage ratio stands at a comfortable 5.31x, suggesting that the company can meet its interest obligations without significant strain. However, the cash conversion cycle (CCC) of 298.85 days indicates potential inefficiencies in converting sales into cash, an area that warrants attention to improve liquidity and operational performance.
Balance Sheet Strength and Financial Ratios
Analyzing EP Biocomposites’ balance sheet reveals a relatively sound financial position, with total borrowings at ₹3.69 Cr and reserves amounting to ₹9.00 Cr. The company has managed to maintain a low debt-to-equity ratio of 0.28, indicating a conservative approach to leveraging, which is often viewed favorably by investors. The return on equity (ROE) stands at 10.2%, suggesting that the company is effectively generating profits from its equity base, although this is below the industry average. Additionally, the price-to-book value (P/BV) ratio of 1.96x indicates that the stock is trading at a premium over its book value, reflecting investor confidence in its growth potential. However, the working capital days have increased, suggesting that the company may face challenges in managing its short-term assets and liabilities efficiently.
Shareholding Pattern and Investor Confidence
The shareholding pattern of EP Biocomposites indicates a strong promoter backing, with promoters holding 70.05% of the shares. This level of control can be a positive signal, suggesting that the management is committed to the company’s long-term vision. However, the absence of foreign institutional investors (FIIs) may raise questions about the stock’s appeal in broader markets. The public holding stands at 29.95%, which represents a reasonably diverse shareholder base, but the number of shareholders has fluctuated, indicating a lack of consistent retail interest. This could imply that while existing investors are confident, attracting new investors may require enhanced communication of the company’s growth story and operational improvements.
Outlook, Risks, and Final Insight
Looking ahead, EP Biocomposites faces both opportunities and challenges. The growing focus on waste management and sustainability presents a promising market for the company. However, rising operational costs and the declining operating profit margin pose significant risks. If the company can streamline its operations and improve the cash conversion cycle, it could enhance profitability and attract more investors. On the flip side, any delays in implementing these improvements could result in continued volatility in earnings and investor sentiment. For retail investors, understanding these dynamics is crucial. Evaluating the strength of the management, ongoing operational adjustments, and broader market trends in waste management will be key factors in appraising the stock’s potential moving forward. With a solid foundation but evident challenges, EP Biocomposites remains a stock to watch closely.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of EP Biocomposites Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| EP Biocomposites Ltd | 16.8 Cr. | 100.0 | 230/90.0 | 18.3 | 63.5 | 0.00 % | 14.3 % | 10.2 % | 10.0 |
| Eco Recycling Ltd | 840 Cr. | 435 | 1,043/416 | 41.0 | 52.5 | 0.00 % | 36.8 % | 84.0 % | 10.0 |
| Antony Waste Handling Cell Ltd | 1,205 Cr. | 424 | 697/408 | 17.5 | 243 | 0.00 % | 12.1 % | 11.3 % | 5.00 |
| Industry Average | 1,022.50 Cr | 319.67 | 25.60 | 119.67 | 0.00% | 21.07% | 35.17% | 8.33 |
Quarterly Result
| Metric | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2.76 | 5.30 | 3.45 | 3.68 | 4.40 | 7.04 | 4.40 | 7.60 |
| Expenses | 2.42 | 4.27 | 2.92 | 3.26 | 4.14 | 5.90 | 3.91 | 6.31 |
| Operating Profit | 0.34 | 1.03 | 0.53 | 0.42 | 0.26 | 1.14 | 0.49 | 1.29 |
| OPM % | 12.32% | 19.43% | 15.36% | 11.41% | 5.91% | 16.19% | 11.14% | 16.97% |
| Other Income | 0.00 | 0.01 | 0.03 | 0.13 | 0.09 | 0.21 | 0.05 | 0.06 |
| Interest | 0.02 | 0.13 | 0.15 | 0.05 | 0.01 | 0.02 | 0.17 | 0.19 |
| Depreciation | 0.01 | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 |
| Profit before tax | 0.31 | 0.85 | 0.36 | 0.45 | 0.29 | 1.28 | 0.32 | 1.10 |
| Tax % | 25.81% | 32.94% | 25.00% | 33.33% | 27.59% | 27.34% | 34.38% | 25.45% |
| Net Profit | 0.24 | 0.57 | 0.27 | 0.30 | 0.22 | 0.93 | 0.21 | 0.83 |
| EPS in Rs | 2.04 | 4.84 | 1.61 | 1.78 | 1.31 | 5.53 | 1.25 | 4.94 |
Last Updated: May 31, 2025, 6:08 am
Below is a detailed analysis of the quarterly data for EP Biocomposites Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 7.60 Cr.. The value appears strong and on an upward trend. It has increased from 4.40 Cr. (Sep 2024) to 7.60 Cr., marking an increase of 3.20 Cr..
- For Expenses, as of Mar 2025, the value is 6.31 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.91 Cr. (Sep 2024) to 6.31 Cr., marking an increase of 2.40 Cr..
- For Operating Profit, as of Mar 2025, the value is 1.29 Cr.. The value appears strong and on an upward trend. It has increased from 0.49 Cr. (Sep 2024) to 1.29 Cr., marking an increase of 0.80 Cr..
- For OPM %, as of Mar 2025, the value is 16.97%. The value appears strong and on an upward trend. It has increased from 11.14% (Sep 2024) to 16.97%, marking an increase of 5.83%.
- For Other Income, as of Mar 2025, the value is 0.06 Cr.. The value appears strong and on an upward trend. It has increased from 0.05 Cr. (Sep 2024) to 0.06 Cr., marking an increase of 0.01 Cr..
- For Interest, as of Mar 2025, the value is 0.19 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.17 Cr. (Sep 2024) to 0.19 Cr., marking an increase of 0.02 Cr..
- For Depreciation, as of Mar 2025, the value is 0.06 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.05 Cr. (Sep 2024) to 0.06 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Mar 2025, the value is 1.10 Cr.. The value appears strong and on an upward trend. It has increased from 0.32 Cr. (Sep 2024) to 1.10 Cr., marking an increase of 0.78 Cr..
- For Tax %, as of Mar 2025, the value is 25.45%. The value appears to be improving (decreasing) as expected. It has decreased from 34.38% (Sep 2024) to 25.45%, marking a decrease of 8.93%.
- For Net Profit, as of Mar 2025, the value is 0.83 Cr.. The value appears strong and on an upward trend. It has increased from 0.21 Cr. (Sep 2024) to 0.83 Cr., marking an increase of 0.62 Cr..
- For EPS in Rs, as of Mar 2025, the value is 4.94. The value appears strong and on an upward trend. It has increased from 1.25 (Sep 2024) to 4.94, marking an increase of 3.69.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:24 am
| Metric | Mar 2020n n 3m | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Sales | 0.57 | 2.95 | 8.06 | 7.12 | 11.43 | 12.01 |
| Expenses | 0.53 | 2.49 | 6.66 | 6.15 | 10.02 | 10.23 |
| Operating Profit | 0.04 | 0.46 | 1.40 | 0.97 | 1.41 | 1.78 |
| OPM % | 7.02% | 15.59% | 17.37% | 13.62% | 12.34% | 14.82% |
| Other Income | 0.00 | 0.00 | 0.02 | 0.17 | 0.30 | 0.11 |
| Interest | 0.00 | 0.00 | 0.19 | 0.23 | 0.04 | 0.36 |
| Depreciation | 0.00 | 0.00 | 0.07 | 0.10 | 0.10 | 0.11 |
| Profit before tax | 0.04 | 0.46 | 1.16 | 0.81 | 1.57 | 1.42 |
| Tax % | 25.00% | 23.91% | 31.03% | 28.40% | 26.75% | 27.46% |
| Net Profit | 0.03 | 0.36 | 0.81 | 0.58 | 1.15 | 1.03 |
| EPS in Rs | 6.00 | 72.00 | 6.88 | 3.45 | 6.84 | 6.13 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|
| YoY Net Profit Growth (%) | 125.00% | -28.40% | 98.28% | -10.43% |
| Change in YoY Net Profit Growth (%) | 0.00% | -153.40% | 126.67% | -108.71% |
EP Biocomposites Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 4 years from 2021-2022 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 84% |
| 3 Years: | 14% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 103% |
| 3 Years: | 8% |
| TTM: | -10% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 15% |
| 3 Years: | 11% |
| Last Year: | 10% |
Last Updated: September 5, 2025, 3:26 pm
Balance Sheet
Last Updated: December 4, 2025, 2:50 am
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.05 | 0.05 | 1.18 | 1.68 | 1.68 | 1.68 | 1.68 |
| Reserves | -0.02 | 0.34 | 0.82 | 6.73 | 7.88 | 8.91 | 9.00 |
| Borrowings | 0.00 | 0.00 | 4.11 | 1.28 | 1.80 | 2.98 | 3.69 |
| Other Liabilities | 0.52 | 0.94 | 3.16 | 2.03 | 3.72 | 3.06 | 1.43 |
| Total Liabilities | 0.55 | 1.33 | 9.27 | 11.72 | 15.08 | 16.63 | 15.80 |
| Fixed Assets | 0.00 | 0.00 | 0.41 | 0.33 | 0.33 | 0.23 | 0.20 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.14 | 0.14 | 0.15 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.55 | 1.33 | 8.86 | 11.39 | 14.61 | 16.26 | 15.45 |
| Total Assets | 0.55 | 1.33 | 9.27 | 11.72 | 15.08 | 16.63 | 15.80 |
Below is a detailed analysis of the balance sheet data for EP Biocomposites Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 1.68 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.68 Cr..
- For Reserves, as of Sep 2025, the value is 9.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.91 Cr. (Mar 2025) to 9.00 Cr., marking an increase of 0.09 Cr..
- For Borrowings, as of Sep 2025, the value is 3.69 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 2.98 Cr. (Mar 2025) to 3.69 Cr., marking an increase of 0.71 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1.43 Cr.. The value appears to be improving (decreasing). It has decreased from 3.06 Cr. (Mar 2025) to 1.43 Cr., marking a decrease of 1.63 Cr..
- For Total Liabilities, as of Sep 2025, the value is 15.80 Cr.. The value appears to be improving (decreasing). It has decreased from 16.63 Cr. (Mar 2025) to 15.80 Cr., marking a decrease of 0.83 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.20 Cr.. The value appears to be declining and may need further review. It has decreased from 0.23 Cr. (Mar 2025) to 0.20 Cr., marking a decrease of 0.03 Cr..
- For CWIP, as of Sep 2025, the value is 0.15 Cr.. The value appears strong and on an upward trend. It has increased from 0.14 Cr. (Mar 2025) to 0.15 Cr., marking an increase of 0.01 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 15.45 Cr.. The value appears to be declining and may need further review. It has decreased from 16.26 Cr. (Mar 2025) to 15.45 Cr., marking a decrease of 0.81 Cr..
- For Total Assets, as of Sep 2025, the value is 15.80 Cr.. The value appears to be declining and may need further review. It has decreased from 16.63 Cr. (Mar 2025) to 15.80 Cr., marking a decrease of 0.83 Cr..
Notably, the Reserves (9.00 Cr.) exceed the Borrowings (3.69 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2020n n 3m | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Free Cash Flow | 0.04 | 0.46 | -2.71 | -0.31 | -0.39 | -1.20 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Debtor Days | 192.11 | 80.42 | 321.53 | 300.41 | 287.40 | 330.05 |
| Inventory Days | 83.65 | 90.25 | 86.83 | 90.58 | 53.86 | 66.66 |
| Days Payable | 349.79 | 128.35 | 161.90 | 104.79 | 153.74 | 97.87 |
| Cash Conversion Cycle | -74.04 | 42.32 | 246.47 | 286.20 | 187.52 | 298.85 |
| Working Capital Days | -57.63 | 25.98 | 156.69 | 255.81 | 217.47 | 270.79 |
| ROCE % | 219.05% | 41.54% | 13.16% | 15.30% | 14.20% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 6.13 | 6.84 | 3.94 | 9.48 | 6.97 |
| Diluted EPS (Rs.) | 6.13 | 6.84 | 3.94 | 9.48 | 6.97 |
| Cash EPS (Rs.) | 6.80 | 7.44 | 4.02 | 7.43 | 71.66 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 63.01 | 56.88 | 50.04 | 16.97 | 77.30 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 63.01 | 56.88 | 50.04 | 16.97 | 77.30 |
| Revenue From Operations / Share (Rs.) | 71.40 | 68.03 | 42.41 | 68.45 | 589.60 |
| PBDIT / Share (Rs.) | 11.20 | 10.15 | 6.64 | 11.79 | 92.90 |
| PBIT / Share (Rs.) | 10.54 | 9.55 | 6.05 | 11.23 | 92.84 |
| PBT / Share (Rs.) | 8.43 | 9.34 | 4.84 | 9.90 | 92.84 |
| Net Profit / Share (Rs.) | 6.13 | 6.84 | 3.43 | 6.87 | 71.60 |
| PBDIT Margin (%) | 15.69 | 14.91 | 15.65 | 17.22 | 15.75 |
| PBIT Margin (%) | 14.75 | 14.03 | 14.26 | 16.40 | 15.74 |
| PBT Margin (%) | 11.80 | 13.72 | 11.41 | 14.46 | 15.74 |
| Net Profit Margin (%) | 8.58 | 10.04 | 8.07 | 10.04 | 12.14 |
| Return on Networth / Equity (%) | 9.72 | 12.02 | 6.84 | 40.50 | 92.62 |
| Return on Capital Employeed (%) | 13.57 | 15.04 | 10.54 | 31.51 | 120.10 |
| Return On Assets (%) | 6.19 | 7.62 | 4.91 | 8.72 | 27.04 |
| Long Term Debt / Equity (X) | 0.23 | 0.11 | 0.14 | 1.09 | 0.00 |
| Total Debt / Equity (X) | 0.28 | 0.18 | 0.15 | 2.06 | 0.00 |
| Asset Turnover Ratio (%) | 0.75 | 0.85 | 0.67 | 1.52 | 3.14 |
| Current Ratio (X) | 3.95 | 2.84 | 4.45 | 1.69 | 1.39 |
| Quick Ratio (X) | 3.55 | 2.60 | 3.96 | 1.46 | 0.90 |
| Inventory Turnover Ratio (X) | 9.82 | 6.05 | 3.56 | 6.98 | 6.39 |
| Interest Coverage Ratio (X) | 5.31 | 48.88 | 5.50 | 8.89 | 0.00 |
| Interest Coverage Ratio (Post Tax) (X) | 3.91 | 33.94 | 3.84 | 6.18 | 0.00 |
| Enterprise Value (Cr.) | 22.11 | 23.59 | 32.97 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 1.84 | 2.06 | 4.62 | 0.00 | 0.00 |
| EV / EBITDA (X) | 11.74 | 13.83 | 29.53 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 1.73 | 2.02 | 4.75 | 0.00 | 0.00 |
| Price / BV (X) | 1.96 | 2.41 | 4.03 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 1.73 | 2.02 | 4.75 | 0.00 | 0.00 |
| EarningsYield | 0.04 | 0.04 | 0.01 | 0.00 | 0.00 |
After reviewing the key financial ratios for EP Biocomposites Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 6.13. This value is within the healthy range. It has decreased from 6.84 (Mar 24) to 6.13, marking a decrease of 0.71.
- For Diluted EPS (Rs.), as of Mar 25, the value is 6.13. This value is within the healthy range. It has decreased from 6.84 (Mar 24) to 6.13, marking a decrease of 0.71.
- For Cash EPS (Rs.), as of Mar 25, the value is 6.80. This value is within the healthy range. It has decreased from 7.44 (Mar 24) to 6.80, marking a decrease of 0.64.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 63.01. It has increased from 56.88 (Mar 24) to 63.01, marking an increase of 6.13.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 63.01. It has increased from 56.88 (Mar 24) to 63.01, marking an increase of 6.13.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 71.40. It has increased from 68.03 (Mar 24) to 71.40, marking an increase of 3.37.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 11.20. This value is within the healthy range. It has increased from 10.15 (Mar 24) to 11.20, marking an increase of 1.05.
- For PBIT / Share (Rs.), as of Mar 25, the value is 10.54. This value is within the healthy range. It has increased from 9.55 (Mar 24) to 10.54, marking an increase of 0.99.
- For PBT / Share (Rs.), as of Mar 25, the value is 8.43. This value is within the healthy range. It has decreased from 9.34 (Mar 24) to 8.43, marking a decrease of 0.91.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 6.13. This value is within the healthy range. It has decreased from 6.84 (Mar 24) to 6.13, marking a decrease of 0.71.
- For PBDIT Margin (%), as of Mar 25, the value is 15.69. This value is within the healthy range. It has increased from 14.91 (Mar 24) to 15.69, marking an increase of 0.78.
- For PBIT Margin (%), as of Mar 25, the value is 14.75. This value is within the healthy range. It has increased from 14.03 (Mar 24) to 14.75, marking an increase of 0.72.
- For PBT Margin (%), as of Mar 25, the value is 11.80. This value is within the healthy range. It has decreased from 13.72 (Mar 24) to 11.80, marking a decrease of 1.92.
- For Net Profit Margin (%), as of Mar 25, the value is 8.58. This value is within the healthy range. It has decreased from 10.04 (Mar 24) to 8.58, marking a decrease of 1.46.
- For Return on Networth / Equity (%), as of Mar 25, the value is 9.72. This value is below the healthy minimum of 15. It has decreased from 12.02 (Mar 24) to 9.72, marking a decrease of 2.30.
- For Return on Capital Employeed (%), as of Mar 25, the value is 13.57. This value is within the healthy range. It has decreased from 15.04 (Mar 24) to 13.57, marking a decrease of 1.47.
- For Return On Assets (%), as of Mar 25, the value is 6.19. This value is within the healthy range. It has decreased from 7.62 (Mar 24) to 6.19, marking a decrease of 1.43.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has increased from 0.11 (Mar 24) to 0.23, marking an increase of 0.12.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.28. This value is within the healthy range. It has increased from 0.18 (Mar 24) to 0.28, marking an increase of 0.10.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.75. It has decreased from 0.85 (Mar 24) to 0.75, marking a decrease of 0.10.
- For Current Ratio (X), as of Mar 25, the value is 3.95. This value exceeds the healthy maximum of 3. It has increased from 2.84 (Mar 24) to 3.95, marking an increase of 1.11.
- For Quick Ratio (X), as of Mar 25, the value is 3.55. This value exceeds the healthy maximum of 2. It has increased from 2.60 (Mar 24) to 3.55, marking an increase of 0.95.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 9.82. This value exceeds the healthy maximum of 8. It has increased from 6.05 (Mar 24) to 9.82, marking an increase of 3.77.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.31. This value is within the healthy range. It has decreased from 48.88 (Mar 24) to 5.31, marking a decrease of 43.57.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.91. This value is within the healthy range. It has decreased from 33.94 (Mar 24) to 3.91, marking a decrease of 30.03.
- For Enterprise Value (Cr.), as of Mar 25, the value is 22.11. It has decreased from 23.59 (Mar 24) to 22.11, marking a decrease of 1.48.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.84. This value is within the healthy range. It has decreased from 2.06 (Mar 24) to 1.84, marking a decrease of 0.22.
- For EV / EBITDA (X), as of Mar 25, the value is 11.74. This value is within the healthy range. It has decreased from 13.83 (Mar 24) to 11.74, marking a decrease of 2.09.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.73. This value is within the healthy range. It has decreased from 2.02 (Mar 24) to 1.73, marking a decrease of 0.29.
- For Price / BV (X), as of Mar 25, the value is 1.96. This value is within the healthy range. It has decreased from 2.41 (Mar 24) to 1.96, marking a decrease of 0.45.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.73. This value is within the healthy range. It has decreased from 2.02 (Mar 24) to 1.73, marking a decrease of 0.29.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in EP Biocomposites Ltd:
- Net Profit Margin: 8.58%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 13.57% (Industry Average ROCE: 21.07%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 9.72% (Industry Average ROE: 35.17%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.91
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.55
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 18.3 (Industry average Stock P/E: 25.6)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.28
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 8.58%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Waste Management | D-2/12, Bicholim Industrial Estate, Bicholim Goa 403504 | info@epkamatgroup.com www.epbiocomposites.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rajkumar Gajanan Kamat | Managing Director |
| Mr. Shreyas Dattatray Nadkarni | Director |
| Ms. Leena Kamat | Director |
| Mr. Nitin Anant Kunkolienker | Independent Director |
| Mr. Dinesh Naguesh Shenoy | Independent Director |
FAQ
What is the intrinsic value of EP Biocomposites Ltd?
EP Biocomposites Ltd's intrinsic value (as of 09 December 2025) is 96.72 which is 3.28% lower the current market price of 100.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 16.8 Cr. market cap, FY2025-2026 high/low of 230/90.0, reserves of ₹9.00 Cr, and liabilities of 15.80 Cr.
What is the Market Cap of EP Biocomposites Ltd?
The Market Cap of EP Biocomposites Ltd is 16.8 Cr..
What is the current Stock Price of EP Biocomposites Ltd as on 09 December 2025?
The current stock price of EP Biocomposites Ltd as on 09 December 2025 is 100.0.
What is the High / Low of EP Biocomposites Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of EP Biocomposites Ltd stocks is 230/90.0.
What is the Stock P/E of EP Biocomposites Ltd?
The Stock P/E of EP Biocomposites Ltd is 18.3.
What is the Book Value of EP Biocomposites Ltd?
The Book Value of EP Biocomposites Ltd is 63.5.
What is the Dividend Yield of EP Biocomposites Ltd?
The Dividend Yield of EP Biocomposites Ltd is 0.00 %.
What is the ROCE of EP Biocomposites Ltd?
The ROCE of EP Biocomposites Ltd is 14.3 %.
What is the ROE of EP Biocomposites Ltd?
The ROE of EP Biocomposites Ltd is 10.2 %.
What is the Face Value of EP Biocomposites Ltd?
The Face Value of EP Biocomposites Ltd is 10.0.